Decreased Central Opioid Activity in Premenstrual Syndrome: Luterinizing Hormone Response to Naloxone

Abstract

Objective: To evaluate central opioid activity in women with prespectively documented premenstrual syndrome (PMS) and control women in the mid- and late luteal phases of the menstrual cycle.

Methods: Blood was collected every 15 minutes 1 hours before (0800) and 2 hours after treatment (0900-1100). The treatment was administered in a randomized fashion and consisted of naloxone 1 or 4 mg or placebo, and blood was assayed for luteinizing hormone (LH). Baseline estradiol, progesterone, and prolactin were measured at 0800 and 0900 hours.

Results: There was a significant increase in LH area under the curve and mean LH in response to naloxone in the midluted phase in the controls (P < .001). The PMS subjects did not display a significant increase in LH concentration in response to naloxone in the midluteal phase. There were no significant LH response to naloxone in either group in the late luteal phase. There were no significant difference in estradiol, progesterone, or prolactin concentrations or estrogen to progesterone ratios between groups.

Conclusion: Control women have on enhanced central opioid tone during the midluteal phase that diminishes and becomes minimal in the late luteal phase of the menstrual cycle. In contrast, women with PMS have a loss of central opioid tone during the midluteal phase as indicated by the loss of LH response to naloxone. This attenuated central opioid tone in women with PMS as compared with asymptomatic control women may play a role in the pathophysiology of PMS.

Keywords

PMS central opioid activity LH response to naloxone

Get full access to this article

View all access options for this article.

References

1. Reid RL . Endogenous opiate peptides and premenstrual syndrome. Semin Reprod Endocrinol 1987;5:191-197.

2. Vargyas J , Lobo R . Mishell DB . Brain opioid activity in the premenstrual syndrome. Fertil Steril 1984;42:324-324.

3. Facchineti F , Martignoni E , Sola D , Petraglia F , Nappi G , Genazzani AR . Transient failure of central opioid tonus and premenstural symptoms. J Reprod Med 1988;33:633-638.

4. Facchinetti F , Genazzani AD , Martignoni E , Fioroni L , Sances G , Genazzani AR . Neuroendocrine correlates of premenstrual syndrome: Changes in the pulsatile pattern of plasma LH. Psychoneuroendocrinology 1990;15:269-277.

5. Chuong CJ , Coulam CB , Kao PC , Bergstralh EJ , Go VLW . Neuropeptide levels in premenstrual syndrome. Fertil Steril 1985;44:760-765.

6. Ferin M , Van Vugt R , Wardlaw S . The hypothalamic control of the menstrual cycle and the role of endogenous opioid peptides. Recent Prog Horm Res 1984;40:441-485.

7. Reid RL , Hoff JD , Yen SC , Li CH . Effects of exogenous βh-endorphin on pituitary hormone secretion and its disappearance rate in normal human subjects. J Clin Endocrinol Metab 1981, 52:1179-1184.

8. Yen SSC , Quigley ME , Reid RL , Ropert JF , Cetel NS . Neuroendocrinology of opioid peptides and their role in the control of gonadotropin and prolactin secretion. Am J Obster Gynecol 1985;152:485-493.

9. Wehrenberg WB , Wardlaw SL , Frantz AG , Ferin M . β-endophin in hypophyseal portal blood: Variations throughout the menstrual cycle. Endocrinology 1982;3:879-881.

10.

10. Wardlaw SL , Wehrenberg WB , Ferin M , Antunes JL , Fratnz AG . Effect of sex steriods on β-endorphin in hypophyseal portal blood. J Clin Endocrinol Metab 1982;55:877-881.

11.

11. Blankstein J . Reyes FI , Winter JSD , Faiman C . Endorphins and the regulation of the human menstrual cycle. Clin Endocrinol 1981;14:287-294.

12.

12. Shoupe D . Montz FJ , Lobo RA . The effects of estrogen and progestin on endogenous opioid activity in oophorectomized women. J Clin Endocrinol Metab 1985;60:178-183.

13.

13. Quigly ME , Yes SSC . The role of endogenous opiates in LH secretion during the menstrual cycle. J Clin Endocrinol Metab 1980;51:179-181.

14.

14. Snowden EU , Khan-Dawood FS , Dawood MY . The effect of naloxone on endogenous opioid regulation of pituitary gonadotropins and prolactin during the menstrual cycle. J Clin Endocrinol Metab 1984;59:298-302.

15.

15. Ropert JF , Quigley ME , Yen SSC . Endogenous opiates modulater pulsatile luternizing hormone release in humans. J Clin Endocrinol Metab 1981;52:583-585.

16.

16. Mendelson JH , Ellingboe J , Keuhnle JC , Mellol NK . Effects of naltrexone on mood and neuroendocrine function in normal adult males. Psychoneuroendocrinology 1979;3:231-236.

17.

17. Cohen MR , Cohen RM , Pickar D , Weingartner H , Murphy DL , Bunney, WE . Behavioral effects after high dose naloxone administration to normal volunteen. Lancet 1981;ii:1110-1110.

18.

18. American Psychiatric Association . Diagnostic and statistical manual of mental disorders-IV. 4th ed. Washington, DC: American Psychiatric Association, 1994.

19.

19. Urban RJ , Johnson ML , Velahuis JD . In vivo biological validation and biophysical modeling of the sensitivity and positive accuracy of endocrine peak detection. Endocrinology 1989;124:2542-2547.

20.

20. Siegel S . Nonparametric statistics for the behavior sciences. New York: McGraw Hill, 1956.

21.

21. Chuong CJ , Hsi BP . Effect of naloxone on luteinizing hormone secretion in premenstrual syndrome. Fertil Steril 1994;61:1039-1044.

22.

22. Zanesi M , Martini L . Effects of progesterone metabolites on gonadotropin secretion. Steroid Biochem 1975;6:1021-1023.

23.

23. Murphy LL , Mahesh VB . Selective release of lutenizing hormone by 3α-hydroxy-5α-pregnan-20-one in immature ovariectomized estrogen-primed rats. Biol Reprod 1994;30:795-803.

24.

24. Brann DW , Putnam CD , and Mahesh VB . GABAA receptors mediate 3α-hydroxy-5α-pregnan-20-one induced gonadotropin secretion. Endocrinology 1990;126:1854-1859.

25.

25. Rapkin AJ , Edelmuth E , McGuire M . Whole-blood serotonin in premenstrual syndrome. Obstet Gynecol 1987;70:533-537.

26.

26. Rapkin AJ , Chang LC , Reading AE , McGuire M . Tryptophan loading test in premenstrual syndrome. J Obstet Gynaecol 1989;10:140-144.

27.

27. Rapkin AJ . The rote of serotonin in premenstrual syndrome. In: Pitkin RM , Scott JR , eds. Clinical Obstetrics and Gynecology. Philadelphia: JB Lippincott, 1992:629-636.

28.

28. Taylor DL , Mathew RJ , Ho BT , Weinman ML . Serotonin levels and platelet uptake during premenstrual tension. Neuropsychiobiology 1984;12:16-18.

29.

29. Ashby CR , Carr LA , Cook CL , Steptoe MM , Franks DD . Alteration of platelet serotonergic mechanisms and monoamine oxidase activity in premenstrual syndrome. Biol Psychiatry 1988;24:225-233.

30.

30. Halbreich, U . Gonadal hormones and antihormones, serotonin and mood. Psychopharmacol Bull 1990;26:291-295.

31.

31. Sandyk R , Bamford CR . Opioid-serotoninergic dysregulation in the pathophysiology of Tourette's syndrome. Funct Neurol 1998;3:225-235.

32.

32. Brase DA . Role of serotonin and gamma-aminobutyric acid in opiod effects. In: Loh HH , Ross DH , eds. Advances in biochemical psychopharmacology. New York: Raven Press 1979; 20:409-428.

33.

33. Parenti M , Tirone F , Olgiati VR , Groppetti A . Presence of opiate receptors on striatal serotonergic nerve terminals. Brain Res 1983;280:317-322.

34.

34. Van Vugt A , Meites J . Influence of endogenous opiates on anterior pituitary function. Federation Proceedings 1980;39:2533-2538.

35.

35. Van Loon GR , De Souza EB . Effects of β-endorphin on brain serotonin metabolism. Life Sci 1978;23:971-978.

36.

36. Foresta C , Scanelli G , Tramarin A , Scandellari C . Serotonin but not dopamine is involved in the naloxone-induced luteinizing hormone release in man. Fertil Steril 1985;43:447-450.

37.

37. Haubrich DR , Blake DE . Modification of serotonin metabolism in rat brain after acute or chornic administration of morphine. Biochem Pharmacol 1973;22:2753-2759.